Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | Direct | 17,786 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,786 · Balance 17,786 F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Loxo Oncology, Inc.
Report date February 15, 2019 · Filed February 15, 2019
Section 16 reporting ended · disclosed 2019-02-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.35 · Expires 2025-04-30 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-02-15 · Disposition to issuer · Disposed 17,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.27 · Expires 2026-12-05 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-02-15 · Disposition to issuer · Disposed 28,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.69 · Expires 2025-12-15 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-02-15 · Disposition to issuer · Disposed 28,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.56 · Expires 2027-03-14 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-02-15 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.88 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-02-15 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.77 · Expires 2029-01-01 | Direct | 0 |
Reported balance
After 2019-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-02-15 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes. F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement") dated January 5, 2019, between Eli Lilly and Company, an Indiana corporation ("Lilly"), Bowfin Acquisition Corporation, Inc., a Delaware corporation and a wholly owned subsidiary of Lilly ("Merger Sub"), and Loxo Oncology, Inc., a Delaware corporation ("Loxo Oncology"), Merger Sub will merge with and into Loxo Oncology, with Loxo Oncology surviving as a wholly owned subsidiary of Lilly (the "Merger"). Pursuant to the Merger Agreement each issued and outstanding shares (the "Shares") of Loxo common stock, par value $0.0001 per share, was purchased at a price of $235.00 per share (the "Offer Price"), net to the seller in cash, without interest, and subject to withholding taxes.
F2: Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each Loxo Oncology stock option that is then-outstanding and unvested shall become immediately vested and exercisable in full. At the Effective Time, each Loxo Oncology stock option that is outstanding under the Loxo Oncology Equity Incentive Plans (including any unvested Loxo stock options for which the vesting was accelerated immediately prior to the Effective Time as described above) will be cancelled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option. Any outstanding option with an exercise price equal to or greater than the Offer Price will be cancelled for no consideration at the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2018 Filed Mar 15, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-18-013688 · doc1.xml · derivative · entry 7 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,600 Underlying: Common Stock · 1,700 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $134.28 | $13,428.00 |
DisclosureSEC source: 0001140361-18-013688 · doc1.xml · nonDerivative · entry 6 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $133.04 | $39,912.00 |
DisclosureSEC source: 0001140361-18-013688 · doc1.xml · nonDerivative · entry 5 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $132.61 to $133.33 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 500 | $131.75 | $65,877.00 |
DisclosureSEC source: 0001140361-18-013688 · doc1.xml · nonDerivative · entry 4 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $131.44 to $132.28 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 700 | $130.23 | $91,160.02 |
DisclosureSEC source: 0001140361-18-013688 · doc1.xml · nonDerivative · entry 3 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $129.85 to $130.75 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $128.85 | $12,885.00 |
DisclosureSEC source: 0001140361-18-013688 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. Read SEC document |
| March 13, 2018 Filed Mar 15, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,700 | $11.35 | $19,295.00 |
DisclosureSEC source: 0001140361-18-013688 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 17:37 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-18-008386 · doc1.xml · derivative · entry 6 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,300 Underlying: Common Stock · 1,700 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 17:37 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $94.73 | $9,473.00 |
DisclosureSEC source: 0001140361-18-008386 · doc1.xml · nonDerivative · entry 5 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 17:37 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 700 | $94.04 | $65,828.07 |
DisclosureSEC source: 0001140361-18-008386 · doc1.xml · nonDerivative · entry 4 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $93.59 to $94.54 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 17:37 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 600 | $92.87 | $55,719.00 |
DisclosureSEC source: 0001140361-18-008386 · doc1.xml · nonDerivative · entry 3 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $92.44 to $93.30 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 17:37 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $91.61 | $27,483.99 |
DisclosureSEC source: 0001140361-18-008386 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $91.26 to $91.79 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 17:37 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,700 | $11.35 | $19,295.00 |
DisclosureSEC source: 0001140361-18-008386 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,500 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-18-002447 · doc1.xml · derivative · entry 3 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 1,500 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,500 | $87.50 | $131,242.80 |
DisclosureSEC source: 0001140361-18-002447 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 16, 2018 Filed Jan 18, 2018 17:02 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,500 | $11.35 | $17,025.00 |
DisclosureSEC source: 0001140361-18-002447 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| January 04, 2018 Filed Jan 5, 2018 19:10 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | GrantEmployee Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $84.88 | $0.00 |
DisclosureSEC source: 0001140361-18-001126 · doc1.xml · derivative · entry 1 Burstein Jennifer · CIK 0001640069 · Senior VP of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-01-03 F1 · derivative.exercise_date: 1/24th of the Shares vest the second month anniversary following January 4, 2018 (the "Grant Date"), then an additional 1/48 vest monthly thereafter; provided however, that if the Company has not filed its next Registration Statement on Form S-8 by the first vesting date, then vesting will begin on the date that the Company files its next Registration Statement on Form S-8, but in any event no later than December 31, 2018 (the earlier of such dates, the "Filing Date"), with vesting from the Filing Date calculated based on 1/48th of the Shares per month, measured from the one-month anniversary of the Grant Date. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 17:44 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-17-046575 · doc1.xml · derivative · entry 4 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 1,700 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 17:44 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 800 | $83.94 | $67,155.76 |
DisclosureSEC source: 0001140361-17-046575 · doc1.xml · nonDerivative · entry 3 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $83.55 to $84.43 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 17:44 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 900 | $82.66 | $74,398.14 |
DisclosureSEC source: 0001140361-17-046575 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $82.29 to $83.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 17:44 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,700 | $11.35 | $19,295.00 |
DisclosureSEC source: 0001140361-17-046575 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:25 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-17-044233 · doc1.xml · derivative · entry 5 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,200 Underlying: Common Stock · 1,700 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:25 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $76.76 | $23,028.99 |
DisclosureSEC source: 0001140361-17-044233 · doc1.xml · nonDerivative · entry 4 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $76.11 to $77.09 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:25 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 300 | $75.18 | $22,554.99 |
DisclosureSEC source: 0001140361-17-044233 · doc1.xml · nonDerivative · entry 3 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $74.79 to $75.47 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:25 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,100 | $74.19 | $81,609.00 |
DisclosureSEC source: 0001140361-17-044233 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $73.78 to $74.61 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 27, 2017 Filed Nov 29, 2017 17:25 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,700 | $11.35 | $19,295.00 |
DisclosureSEC source: 0001140361-17-044233 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 17:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-17-040555 · doc1.xml · derivative · entry 5 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,900 Underlying: Common Stock · 1,700 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F6 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 17:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $88.55 | $17,710.00 |
DisclosureSEC source: 0001140361-17-040555 · doc1.xml · nonDerivative · entry 4 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F5 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $88.50 to $88.60 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 17:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 200 | $87.77 | $17,554.70 |
DisclosureSEC source: 0001140361-17-040555 · doc1.xml · nonDerivative · entry 3 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $87.47 to $88.07 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 17:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,300 | $86.89 | $112,954.01 |
DisclosureSEC source: 0001140361-17-040555 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $86.36 to $87.12 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 30, 2017 Filed Nov 1, 2017 17:08 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,700 | $11.35 | $19,295.00 |
DisclosureSEC source: 0001140361-17-040555 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:09 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-17-036062 · doc1.xml · derivative · entry 5 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,600 Underlying: Common Stock · 1,700 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:09 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 100 | $90.11 | $9,011.00 |
DisclosureSEC source: 0001140361-17-036062 · doc1.xml · nonDerivative · entry 4 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:09 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 957 | $89.50 | $85,650.06 |
DisclosureSEC source: 0001140361-17-036062 · doc1.xml · nonDerivative · entry 3 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $89.08 to $89.98 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:09 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 643 | $88.35 | $56,808.66 |
DisclosureSEC source: 0001140361-17-036062 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,057 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $87.93 to $88.87 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 17:09 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,700 | $11.35 | $19,295.00 |
DisclosureSEC source: 0001140361-17-036062 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 17:24 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,700 | $0.00 Strike: $11.35 | $0.00 |
DisclosureSEC source: 0001140361-17-032484 · doc1.xml · derivative · entry 4 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,300 Underlying: Common Stock · 1,700 shares Expires 2025-04-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the one-year anniversary of the Reporting Person's employment commencement date, and thereafter vests as to 1/48th of the shares in equal monthly installments. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 17:24 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 600 | $74.17 | $44,500.02 |
DisclosureSEC source: 0001140361-17-032484 · doc1.xml · nonDerivative · entry 3 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F4 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $73.97 to $74.64 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 17:24 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | SaleCommon Stock | 1,100 | $73.50 | $80,847.03 |
DisclosureSEC source: 0001140361-17-032484 · doc1.xml · nonDerivative · entry 2 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. F2 · shares: Represents the aggregate of sales effected on the same day at different prices. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $72.91 to $73.88 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 17:24 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | Exercise / conversionCommon Stock | 1,700 | $11.35 | $19,295.00 |
DisclosureSEC source: 0001140361-17-032484 · doc1.xml · nonDerivative · entry 1 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 15, 2017 Filed Mar 17, 2017 17:14 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | GrantEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $43.56 | $0.00 |
DisclosureSEC source: 0001140361-17-012610 · doc1.xml · derivative · entry 1 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 06, 2016 Filed Dec 8, 2016 19:31 UTC | Loxo Oncology, Inc. LOXO · Entity 160155 | GrantEmployee Stock Option (right to buy) · Derivative | 28,000 | $0.00 Strike: $26.27 | $0.00 |
DisclosureSEC source: 0001140361-16-089153 · doc1.xml · derivative · entry 1 Burstein Jennifer · CIK 0001640069 · Vice President of Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2026-12-05 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the grant date, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.